GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (FRA:4GB) » Definitions » Ending Cash Position

Gossamer Bio (FRA:4GB) Ending Cash Position : €80.71 Mil (As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Gossamer Bio Ending Cash Position?

Gossamer Bio's Ending Cash Position for the quarter that ended in Jun. 2024 was €80.71 Mil.

Gossamer Bio's quarterly Ending Cash Position increased from Dec. 2023 (€29.44 Mil) to Mar. 2024 (€35.75 Mil) and increased from Mar. 2024 (€35.75 Mil) to Jun. 2024 (€80.71 Mil).

Gossamer Bio's annual Ending Cash Position declined from Dec. 2021 (€162.37 Mil) to Dec. 2022 (€105.70 Mil) and declined from Dec. 2022 (€105.70 Mil) to Dec. 2023 (€29.44 Mil).

Gossamer Bio Ending Cash Position Historical Data

The historical data trend for Gossamer Bio's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gossamer Bio Ending Cash Position Chart

Gossamer Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial 121.58 400.00 162.37 105.70 29.44

Gossamer Bio Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.16 77.41 29.44 35.75 80.71

Gossamer Bio Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Gossamer Bio's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=102.679+-73.235
=29.44

Gossamer Bio's Ending Cash Position for the quarter that ended in Jun. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=36.104+44.605
=80.71

Gossamer Bio Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Gossamer Bio's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Gossamer Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gossamer Bio Inc (FRA:4GB) » Definitions » Ending Cash Position
Comparable Companies
ABSI TSVT DSGN CDT ACRV SEER CYT BTAI TRVI CDXS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
GOSS:USA
Address
3013 Science Park Road, Suite 200, San Diego, CA, USA, 92121
Website
https://www.gossamerbio.com
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

Gossamer Bio Headlines

No Headlines